Health Care • Biotechnology: Pharmaceutical Preparations
$0.62 ▼ -0.02
(-3.84%)
MKT CAP: $45.1M • VOL: 690.7K
52W L $1 52W H $2
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
BMEA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$83.5M | -$144.1M | -$126.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$61.8M | -$138.4M | -$117.3M |
| EBITDA (Normalized) | — | -$143.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$70.4M | -$119.9M | -$96.6M |
| Capital Expenditures (CapEx) | — | $362.0K | — |
| Free Cash Flow (FCF) | -$70.4M | -$120.3M | -$96.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $55.8M | $58.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $29.6M | $51.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BMEA.